Press release
GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits
Nadrich & Cohen, LLP reports that GlaxoSmithKline has agreed to settle approximately 20,000 Avandia side effects lawsuits.Los Angeles, CA, February 3, 2012 – UK drug-maker GlaxoSmithKline has agreed to settle 20,000 Avandia side effects lawsuits. According to a Bloomberg report, the company previously agreed to pay at least $700 million to settle more than 15,000 claims on behalf of patients who said that the drug caused heart attacks, strokes and other complications.
Avandia (rosiglitazone) was first approved by the FDA in 1999 to treat Type 2 diabetes in adult patients. The drug hit the market the same year as another popular diabetes drug, Actos (pioglitazone). The maker of Actos, Takeda Pharmaceuticals, is now facing numerous lawsuits from patients who claim the drug caused them to develop bladder cancer.
GlaxoSmithKline announced in November 2011 that it would $3 billion to the federal government in connection with claims that the company had illegally marketed Avandia. In addition to the 20,000 cases involved in the settlement agreement, Avandia side effects claims are still pending in state courts across the country. An estimated 2,500 federal lawsuits that were consolidated in a Philadelphia court have also been assigned to mediation.
Patients who experienced complications after using Avandia are encouraged to complete a MedWatch form by visiting the FDA’s website. Patients are also urged to seek the aid of an experienced personal injury lawyer to discuss their legal rights.
Nadrich & Cohen LLP is offering confidential, no-cost consultations to individuals across the country who believe they were harmed by Avandia. Help is available by calling the firm’s injury hotline at 1-800-718-4658.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling Avandia side effects claims, the firm is also investigating cases involving Accutane, Actos, Zoloft, Fosamax, Paxil, Vaginal Mesh, Wright Conserve Hips, Yaz, Yasmin, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. For more information, visit www.personalinjurylawcal.com.
Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits here
News-ID: 209672 • Views: …
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation.
Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed…
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.
Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.…
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants.
Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems.
The two-day panel, which is expected…
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the…
More Releases for Avandia
Paracetamol Manufacturing Plant Report 2024: Business Plan, Raw Material Require …
IMARC Group's report titled "Paracetamol Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing a paracetamol manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more.
In addition to the…
Aluminium Cans Manufacturing Plant Cost Report 2024: Business Plan, Inventory Ma …
IMARC Group's report titled "𝗔𝗹𝘂𝗺𝗶𝗻𝗶𝘂𝗺 𝗖𝗮𝗻𝘀 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗣𝗹𝗮𝗻𝘁 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝟮𝟬𝟮𝟰: 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗧𝗿𝗲𝗻𝗱𝘀, 𝗣𝗹𝗮𝗻𝘁 𝗦𝗲𝘁𝘂𝗽, 𝗠𝗮𝗰𝗵𝗶𝗻𝗲𝗿𝘆, 𝗥𝗮𝘄 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹𝘀, 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀, 𝗖𝗼𝘀𝘁 𝗮𝗻𝗱 𝗥𝗲𝘃𝗲𝗻𝘂𝗲" provides a comprehensive guide for establishing an aluminium cans manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more.
In addition…
Aluminium Cans Manufacturing Plant Project Report 2024 Edition, Requirements for …
IMARC Group's report titled "𝐀𝐥𝐮𝐦𝐢𝐧𝐢𝐮𝐦 𝐂𝐚𝐧𝐬 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐏𝐥𝐚𝐧𝐭 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟒: 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐓𝐫𝐞𝐧𝐝𝐬, 𝐏𝐥𝐚𝐧𝐭 𝐒𝐞𝐭𝐮𝐩, 𝐌𝐚𝐜𝐡𝐢𝐧𝐞𝐫𝐲, 𝐑𝐚𝐰 𝐌𝐚𝐭𝐞𝐫𝐢𝐚𝐥𝐬, 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬, 𝐂𝐨𝐬𝐭 𝐚𝐧𝐝 𝐑𝐞𝐯𝐞𝐧𝐮𝐞" provides a comprehensive guide for establishing an aluminium cans manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more.
In addition…
Drug Safety Solutions and Pharmacovigilance Market is expected to reach USD 13.9 …
The rising prevalence of adverse drug reactions (ADRs) is the primary driver of the drug safety solutions and pharmacovigilance market. Furthermore, the increasing adoption of pharmacovigilance software by outsourcing companies and strict government regulations for drug prior and post-commercialization contribute to the market's overall growth. The market is expected to benefit from research collaborations and partnerships, as well as drug safety solutions and pharmacovigilance automation, which aid in achieving more…
Metabolic Disorder Therapeutics Market 2023 Share, Size, Key Players, Revenue An …
The Metabolic Disorder Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Metabolic Disorder Therapeutics market. This report explores all the key factors affecting the growth of the global Metabolic Disorder…
Metabolic Disorder Therapeutics Market 2023 Is Ready to Set Outstanding Growth i …
Report Overview
The United Kingdom Metabolic Disorders market is USD XXs billion in 2019 and it is growing at a CAGR of 7.2% during the forecast period (2019-2028).
As per the National Health Service, UK, 28.7% of adults in England were obese and 35.6% were overweight. Of obese adults, nearly 1 in 8 are morbidly obese (3.6% of all adults). Diabetes is a form of metabolic disorder, which results in an increasing…